The first preparations of iodine-labelled human fibrinogen made a few years ago (Christensen 1958 , Hammond & Verel 1959 were clearly overiodinated. The stigmata of a denatured protein were visible in the results from the injected patients, notably high fractional catabolic rates which fell away rapidly in the first few days and abnormally large values for the proportion of total fibrinogen in the extravascular pool. When it was realized that animal and human fibrinogens, unlike most plasma proteins, will not tolerate more than a mean of 0-5 atoms iodine per molecule of 160,000 molecular weight without showing signs of denaturation, the defect was soon corrected. Evidence that denaturation had been avoided was forthcoming with a demonstration of identity of behaviour in the same animal of iodineand biosynthetic 14C-labelled fibrinogen and, in another animal, of iodine-labelled fibrinogen and the same protein after biological screening for 12-18 hours (McFarlane 1963).
Catabolism of Iodine-labelled Fibrinogen
The first preparations of iodine-labelled human fibrinogen made a few years ago (Christensen 1958 , Hammond & Verel 1959 were clearly overiodinated. The stigmata of a denatured protein were visible in the results from the injected patients, notably high fractional catabolic rates which fell away rapidly in the first few days and abnormally large values for the proportion of total fibrinogen in the extravascular pool. When it was realized that animal and human fibrinogens, unlike most plasma proteins, will not tolerate more than a mean of 0-5 atoms iodine per molecule of 160,000 molecular weight without showing signs of denaturation, the defect was soon corrected. Evidence that denaturation had been avoided was forthcoming with a demonstration of identity of behaviour in the same animal of iodineand biosynthetic 14C-labelled fibrinogen and, in another animal, of iodine-labelled fibrinogen and the same protein after biological screening for 12-18 hours (McFarlane 1963) .
In normal man a properly iodinated fibrinogen gives a constant fractional catabolic rate of 25-35 % of the plasma pool per day and data which are compatible with 15-20% of the total fibrinogen being extravascular (McFarlane et al. 1964 ). lodination does not appear to affect the coagulability or general chemical stability of the protein. A difficulty, which is no greater than with the unlabelled protein, is to prevent fibrinolysis during storage in solution. 1251-fibrinogen solutions have been stored by us at -25°C for six months without signs of fibrinolysis but solutions when stored at +4°C, even those containing 0.1 M epsilon aminocaproic acid, have gradually lost coagulability. The labelled protein dries satisfactorily from the frozen state in the presence of salt and then keeps well at +4°C. It also reconstitutes with water to a clear solution so that drying may prove to be the most convenient method ofpreservation.
The practice at Mill Hill has been to prepare human fibrinogen by ammonium sulphate precipitation of fresh heparin or EDTA plasmas from patients as required, but when modest volumes of plasma were used yields have often been barely adequate even when only 10 mg fibrinogen was required for an iodination. The preparation procedure is also tedious and it would be convenient to have a reliable commercial supply of the protein. Dried human fibrinogen from Kabi of Stockholm has been used recently with encouraging results, there being no evidence to suggest that autologous fibrinogen offers any advantages over the homologous variety for turnover measurements. Reconstituted Kabi fibrinogens, which were 90-95% coagulable, iodinated consistently with efficiencies of 65%, i.e. 65 % of the carrier-free radioactivity became firmly bound to the protein. Non-protein-bound activity in the final product was approximately 0-15 % of the total.
Catabolism becomes evident within minutes of injecting a labelled protein when the proportion of non-bound activity in plasma samples begins to rise. Most of the labelled iodide which is liberated in the first few hours is retained in the body water at the end of this time and only after 24-48 hours does urinary excretion of the isotope become a quantitative index of catabolism. In addition daily urinary excretions are erratic and two curves show ioieactivities pern ml inpzwranpes taken in theI s1hours4fter the injection. Te actjvityof l lIfio4defrmthewaolism of albumlt rhs stealy whereas that of-114odlde from the cataboltun ofibrinogen has a maximum value at approximately 140 minutes for reasonable accuracies a mean value for the fraCtional catabolic rate has to be obtained by averagng daily values over six to seven ays.
It is now apprciate that considerable advantase: can be had from nmasuring the ricentration of non-protein-bound activity in the body water in the first twenty-four hours. Individual unrnary activities at this tim must be modified by additions or subtractions of chans in body water iodide activity during the colltion interval to reliably reflect catabolism. Urine collections can even be dispensed with if blood samples are taken over an interval of several hours to enable curves of rising iodide activity to be plotted. In such a case 13Ior '321-iodide should be injected along with the 125I-fibinogen to measure the fractional excretion rate for iodide at this time, a choice of mathematical procedures being available for converting this information into fractional catabolic rates (Donato et al. 1967 , Koj & McFarlane 1968 ). If ai inJected protein has denatured material in it the steady build-up of 'MI-iodide is replaced by the appearance of extra similarly-labelled iodide beginning at 20-30 minutes. This comes from the catabolism of denatured protein in reticuloendothelial cells and is seen as a 'bulge' superimposed on the normal rising curve of luI-iodide activity (cf. Fig 1) . Based on the disappearance rate of injected 1312-iodide and the area under the bulge on the 1251 curve a minimum value for the proportion of denatured protein presnt can be calculated. If it can be assumed that all the denatured protein has been catabolized during the period of the 'bulge', then the method gives a true value for the proportion of denatured protein; in effect, the recipient provides two catabolic rates, one measured before and the other after biological screening of the injected fibrinogen. The method will measure than 1 % of denatured protein, amounts which are not detectabIle by other means. As was t, deliberate over-iodination produced a large bulge, and lesser.ones have been produced conveniently by d irradiation of the prtein before iodiantion (McFarlane & Koj, in preparation) . Intravascular coagulation of injected labelled fibrinogen can also be dramatically reveaed in spite of the fact that in most cases a proportion of the coagulated activity reappes prompty as protin-bound activity in the serumn It will be apated that if similarly labeled iodide happehs to be injected-along with -the labelled fibrinogen it will provide a back-ground level of iodide activity in the body water against which the accumulation of iodide freshly liberated by catabolism has to be recognized. For this reason the injected protein should have a socalled 'PTA value' of the order of 0-15% and anything above 0 5% greatly complicates the interpretation of the results. Phosphotungstic acid (PTA) is preferred to trichloroacetic acid as precipitant. Ion-exchange resins are effective in reducing fibrinogen PTA values to levels which are satisfactory for this method to be used, and provided they are in the citrate form have no adverse effects on the protein. PTA values which tend to rise during storage of the sterile protein can be brought back to the original value by a second resin treatment.
In the course of analysing the results of 17 recent turnover investigations in which a variety of labelled fibrinogens were used on patients, it was noticed that in only two was a 'bulge' entirely absent from the curve of iodide counts, and these were the only two in which the fibrinogen for labelling had been prepared free of its lowsolubility component. I am indebted to Dr E Regoeczi for drawing my attention to the scanty literature on this material and also for his help in preparing a sample of the rabbit protein which, like the human one, is precipitated by standing in the cold and by ammonium sulphate at 18-19% saturation. His particular interest in it arose out of successful attempts to obtain fibrinogen solutions which could be stored frozen without coagulating or precipitating on thawing. Solutions of low-solubility fibrinogen have a high viscosity and filter slowly and no doubt the relative insignificance of the iodide 'bulges' which were observed in the other 15 experiments reflects the fact that most of this labelled component had been filtered out of the original fibrinogens. Certainly a 311-low-solubility fibrinogen and a 12"I-high-solubility one, both 97% coagulable, gave in the same rabbit entirely different catabolic rates, 70 % of the low-solubility material being catabolized in six hours compared with 10% of the high-solubility one (McFarlane & Regoeczi 1969, unpublished observations). Table 1 shows results which are typical of many obtained with 125I-Kabi fibrinogens labelled by us with 0 5 atoms iodine and injected into patients who were not believed to be suffering from abnormalities of fibrinogen turnover. By contrast Table 2 shows < corresponding data from a cardiac patient into whom a commercial 125[_ fibrinogen was injected. The steady but accelerated rate of disappearance of the labelled protein from the plasma in the latter case along with correspondingly increased urinary excretions of the isotope are symptomatic of an over-iodinated protein which is clearly valueless as an indicator of fibrinogen distribution or catabolism. Kabi fibrinogen labelled at 0 5 atoms has always contained at least 1 % of rapidly catabolized material, However, if relatively simple steps are taken in preparing the protein to reject the low-solubility component, there is no reason why a 1251-fibrinogen adequate for all clinical purposes, including the most exacting catabolic studies, should not be made commercially available.
